Multiple myeloma : risk factors, diagnosis, and treatments / Steve Holt, editor.

Online resource; title from PDF title page (EBSCO, viewed October 17, 2014).

""MULTIPLE MYELOMA: RISK FACTORS, DIAGNOSIS AND TREATMENTS""; ""MULTIPLE MYELOMA: RISK FACTORS, DIAGNOSIS AND TREATMENTS""; ""Library of Congress Cataloging-in-Publication Data""; ""Contents""; ""Preface""; ""Chapter 1: Recent Advances in Diagnosis and Treatment of Multiple Myeloma""; ""Abstract""; ""Introduction""; ""Current Therapies for Newly Diagnosed MM""; ""Novel Targeted Therapies for MM""; ""Conclusion""; ""Acknowledgment""; ""References""; ""Chapter 2: Development of Proteasome Inhibitors for the Treatment of Multiple Myeloma""; ""Abstract""; ""Introduction""

""Ubiquitin-Dependent Proteolysis""""Proteasome Inhibitors""; ""Bortezomib""; ""Bortezomib in Preclinical Studies on Human Myeloma Cell Lines and Primary Patient Multiple Myeloma Cells""; ""Bortezomib in Relapsed and/or Refractory Multiple Myeloma -- Clinical Studies""; ""The Second-Generation Proteasome Inhibitors with More Potency and Fewer Side-Effects Studied in Multiple Myeloma""; ""Conclusion and Perspectives""; ""Acknowledgments""; ""References""

""Chapter 3: Cereblon as the Cellular Target Responsible for the Anti-Multiple Myeloma Activity of Immunomodulatory Drugs (Thalidomide, Lenalidomide and Pomalidomide)""""Abstract""; ""Introduction""; ""Cereblon and Its Role in Memory and Learning""; ""Cereblon as a Negative Modulator of the Adenosine Monophosphate-Activated Protein Kinase (AMPK)""; ""Immunomodulatory Drugs""; ""Mechanism of Immunomodulatory Drugs Action in the Treatment of Multiple Myeloma""; ""Immunomodulatory Activities of IMiDs""; ""Anti-Angiogenic Properties of IMiDs""

""Inhibition of Cell Cycle and Induction of Apoptosis by IMiDs""""Disruption of Bone Marrow Stromal Support for Malignant MM Cells""; ""Effect of IMiDs on Myeloma Cell Proliferation""; ""Cereblon as the Direct Target Protein of IMiDs""; ""Cereblon as a Primary Target for Thalidomide Teratogenicity""; ""The Role of Ikaros Family Proteins in IMiDs and CRBN Mechanism""; ""Measurement of Cereblon mRNA and Cereblon Protein Levels as Biomarkers for IMiDs Response""; ""Conclusion and Perspectives""; ""Acknowledgments""; ""References""

""Chapter 4: Review of Risk Factors, Diagnosis Criteria and Treatment in Multiple Myeloma""""Abstract""; ""Introduction""; ""Risk Factors""; ""Diagnosis""; ""Treatment""; ""When Should Treatment Be Started?""; ""Choice Initial Drug Therapy""; ""Transplantation""; ""Consolidation and Maintenance Therapy After Transplantation""; ""Treatment Options for Unfit Patient""; ""References""; ""Chapter 5: Diagnosis and Management of Oral Manifestations of Multiple Myeloma""; ""Abstract""; ""1. Incidence and Case Series""; ""2. Clinical Diagnosis""; ""3. Diagnostic Imaging""

Multiple myeloma (MM) is a hematological malignancy characterized by the clonal expansion of monoclonal immunoglobulin-secreting plasma cells in the bone marrow (BM). MM is associated with lytic bone lesions, anemia, immunodeficiency, and renal impairment. Multiple myeloma accounts for more than 10% of all hematologic malignancies and about 1% of all cancers. Multiple myeloma remains mostly incurable despite conventional intensive high dose chemotherapy followed by hematopoietic stem cell transplant. The costs associated with multiple myeloma are among the highest. This book discusses the diag.

eBooks on EBSCOhost EBSCO eBook Subscription Academic Collection - Worldwide